Zheng Quan Ri Bao Wang·2025-05-29 07:47Group 1 - Fosun Pharma has entered into an exclusive overseas commercialization rights collaboration with Jiuyuan Gene, acquiring rights for products such as Semaglutide, Bone Health, and JY-23 in the Middle East, North Africa, and certain ASEAN countries [1] - The company has established a mature commercialization network in Africa, covering over 40 countries and regions, primarily focusing on English and French-speaking areas south of the Sahara for pharmaceutical product distribution [1] - In the Middle East, Fosun Pharma has strategic partnerships with leading healthcare groups, including Fakeeh Care Group, to advance innovative therapies such as biopharmaceuticals and CAR-T cell therapy in Saudi Arabia [1] Group 2 - The chairman of Fosun Pharma, Chen Yuqing, emphasized that this collaboration represents a significant milestone in the company's globalization strategy, aiming to address unmet clinical needs and benefit more global patients through innovative product deployment [2]